The survey revealed that anxiety scores were at the highest levels since April 2020
News
Push Doctor partners with Well Pharmacy on UK’s first ‘pharmacy-first’ digital service
Over 50,000 patients will have direct access to local community pharmacists
UCB’s bimekizumab data in plaque psoriasis published in The Lancet
Phase III BE VIVID and BE READY studies both met their co-primary endpoints
Keytruda recommended for routine NHS use in lung cancer
Immunotherapy recommended for patients with or without PD-L1 tumour expression
Multiple rolling reviews kick-off for Novavax’s COVID-19 vaccine
Jab recently demonstrated 89.3% efficacy in UK trial
NICE launches public consultation for process review
Proposals include changes to NICE’s Highly Specialised Technologies programme
AstraZeneca and UCL to collaborate on two immuno-oncology projects
Projects will investigate immune checkpoints and contribute to the development of new cancer treatments
Exonate launches diabetic macular oedema trial
Study of lead asset is part of a collaboration with Janssen Pharmaceuticals
UK trial will evaluate safety of mixing different COVID-19 vaccines
Com-Cov study will be the first in the world to evaluate using different vaccines in a two-dose regimen
Health leaders urge public to have symptoms checked on World Cancer Day
Latest NHS data shows less people are being referred for certain cancers
BMS’ deucravacitinib beats Otezla in psoriasis study
The drug met both co-primary endpoints compared to placebo in the trial
NICE green light for GSK’s Nucala
Final guidance on the drug’s use to treat patients with severe eosinophilic asthma on the NHS has now been published
Patients gain early access to Pfizer’s atopic dermatitis drug
The MHRA has issued a positive scientific opinion for abrocitinib allowing its use via the early access to medicines scheme (EAMS)
New analysis backs safety, efficacy of AZ/Oxford COVID-19 jab
The data show 100% protection against severe disease, hospitalisation and death, greater vaccine efficacy with an inter-dose interval of 12 weeks or more, and the potential for reduced asymptomatic transmission
Novo Nordisk’s Sogroya moves closer towards EU approval
CHMP recommended marketing authorisation for human growth hormone therapy
